MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Athira Pharma, Inc. - Common Stock (NQ:ATHA)

6.750 UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Athira Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Alzheimer’s Treatment Market Is Anticipated To Reach $2 Billion By The End Of 2027
Via FinancialNewsMedia
Topics Death
News headline image
Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Athira Pharma, Inc. (ATHA) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Continues Investigation of Athira Pharma, Inc. (ATHA) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Athira Pharma, Inc. and Encourages Investors with Losses to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Athira Pharma, Inc. (ATHA) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Athira Pharma, Inc. and Encourages Investors with Losses to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
ATHIRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Athira Pharma, Inc. on Behalf of Athira Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
Lost Money in Athira Pharma, Inc.?
From Gibbs Law Group
Via Business Wire
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Athira Pharma, Inc. (ATHA) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Announces Investigation of Athira Pharma, Inc. (ATHA) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Athira Pharma, Inc. (ATHA) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
58 Biggest Movers From Friday ↗
Gainers CAI International, Inc. (NYSE: CAI) shares surged 46.9% to close at $56.05 on Friday after the company agreed to a $1.1 billion takeover by Mitsubishi HC Capital Inc.... 
Via Benzinga
News headline image
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Athira Pharma, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
Why Athira Pharma Crashed Today ↗
There was a big shakeup in the biotech's C-suite. 
Via The Motley Fool
News headline image
Mid-Afternoon Market Update: Dow Tumbles Over 400 Points; CAI International Shares Spike Higher ↗
Toward the end of trading Friday, the Dow traded down 1.27% to 33,394.86 while the NASDAQ fell 0.92% to 14,031.05. The S&P also fell, dropping 1.03% to 4,178.31. The U.S. has... 
Via Benzinga
Topics Stocks
News headline image
Wall Street In Fives: Must Read Lists At Midday - Friday, June 18 ↗
Get caught up quickly on the top news and calls moving stocks with these 
Via Talk Markets
News headline image
Mid-Day Market Update: Crude Oil Rises Over 1%; Orphazyme Shares Plunge ↗
Midway through trading Friday, the Dow traded down 1.13% to 33,440.28 while the NASDAQ fell 0.74% to 14,056.31. The S&P also fell, dropping 0.92% to 4,183.07. The U.S. has the... 
Via Benzinga
Topics Stocks
News headline image
32 Stocks Moving In Friday's Mid-Day Session ↗
Gainers CAI International, Inc. (NYSE: CAI) shares jumped 46.4% to $55.86 after the company agreed to a $1.1 billion takeover by Mitsubishi HC Capital Inc. Sykes Enterprises,... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
Before 10 a.m. ET on Friday, 29 companies hit new 52-week lows. Noteables: The largest company in terms of market cap to set a new 52-week low was China Life Insurance Co... 
Via Benzinga
News headline image
Mid-Morning Market Update: Markets Open Lower; Adobe Reports Upbeat Q2 Earnings ↗
Following the market opening Friday, the Dow traded down 1.25% to 33,401.59 while the NASDAQ fell 0.54% to 14,085.56. The S&P also fell, dropping 0.86% to 4,185.44. The U.S.... 
Via Benzinga
Topics Stocks
News headline image
The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17) 10x Genomics, Inc. (NASDAQ... 
Via Benzinga
News headline image
28 Stocks Moving in Friday's Pre-Market Session ↗
Gainers CAI International, Inc. (NYSE: CAI) rose 45.1% to $55.35 in pre-market trading after the company agreed to a $1.1 billion takeover by Mitsubishi HC Capital Inc. Geron... 
Via Benzinga
News headline image
Athira Pharma Stock Plummets After CEO Placed On Temporary Leave ↗
Athira Pharma Inc (NASDAQ: ATHA) CEO Leen Kawas has been placed on temporary leave until the company completes a review “stemming from doctoral research Dr.... 
Via Benzinga
News headline image
Biogen Snagged: Will Hefty Price Tag Hinder Alzheimer's Drug Use? ↗
Biogen stock dipped Tuesday as analysts questioned how much use its potential blockbuster Alzheimer's treatment, Aduhelm, would ultimately secure. 
Via Investor's Business Daily
News headline image
Biogen Wins Landmark Alzheimer's Approval: 5 Things To Know About Aducanumab ↗
The FDA approved Biogen's Alzheimer's treatment, aducanumab, on Monday — though Biogen stock remained halted into the long-awaited decision. 
Via Investor's Business Daily
News headline image
The Fight Against Alzheimer's Reaches A Moment Of Truth For Biogen, Other Biotech Stocks ↗
The FDA will soon review aducanumab, possibly the first new Alzheimer's treatment in years. Stakes are high for Biogen stock — and other biotech stocks too. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story